High-Throughput Sequencing of Plasma MicroRNA in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis

Ekua W. Brenu1,2, Kevin J. Ashton3, Jana Batovska3, Donald R. Staines2,4, Sonya M. Marshall-Gradisnik1,2

1 School of Medical Science, Griffith Health Centre, Griffith University, Gold Coast, Queensland, Australia, 2 The National Centre for Neuroimmunology and Emerging Diseases, Griffith University, Gold Coast, Queensland, Australia, 3 Faculty of Health Sciences and Medicine, Bond University, Robina, Queensland, Australia, 4 Queensland Health, Gold Coast Public Health Unit, Robina, Gold Coast, Queensland, Australia

Abstract

Background: MicroRNAs (miRNAs) are known to regulate many biological processes and their dysregulation has been associated with a variety of diseases including Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME). The recent discovery of stable and reproducible miRNA in plasma has raised the possibility that circulating miRNAs may serve as novel diagnostic markers. The objective of this study was to determine the role of plasma miRNA in CFS/ME.

Results: Using Illumina high-throughput sequencing we identified 19 miRNAs that were differentially expressed in the plasma of CFS/ME patients in comparison to non-fatigued controls. Following RT-qPCR analysis, we were able to confirm the significant up-regulation of three miRNAs (hsa-miR-127-3p, hsa-miR-142-5p and hsa-miR-143-3p) in the CFS/ME patients.

Conclusion: Our study is the first to identify circulating miRNAs from CFS/ME patients and also to confirm three differentially expressed circulating miRNAs in CFS/ME patients, providing a basis for further study to find useful CFS/ME biomarkers.

Introduction

Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is known to affect about 1–4% of individuals worldwide [1,2]. CFS/ME is a multi-symptom disorder including profound disabling fatigue and post-exertional sickness, cognitive disturbances, tender or painful lymph nodes, muscle ache and pain and irregular sleep patterns [3]. There is evidence to suggest a dominant disruption of immunological process in CFS/ME and this may be characterised by reduced cytotoxic activity and increases in regulatory T cells [4,5,6]. In addition patients with CFS/ME may display differential expression in the mRNA and microRNA (miRNA) genes that regulate various physiological processes known to be dysregulated in CFS/ME including cytotoxicity, cytokine secretion and apoptosis [4,7,8,9,10,11,12]. Despite intensive research the pathophysiology of CFS/ME is not yet fully understood and clear diagnostic biomarkers remain elusive.

MicroRNAs are a class of small (typically 18–25 nucleotides in size) single-stranded, non-coding RNAs that regulate gene expression at the post-transcriptional level [13]. Their regulatory roles have been implicated in most biological processes including immunological, neurological and physiological processes [14,15,16,17]. Differential expression of miRNA has been associated with over 300 diseases, including cancer, cardiomyopathy, neurological disorders and unexplained disorders such as CFS/ME [4,18,19,20,21]. Stable and reproducible extracellular miRNAs circulating in blood and present in other biofluids have recently been identified [16]. It has been proposed that these miRNAs have the potential to be utilised as non-invasive novel biomarkers for disease diagnosis and prognosis [22,23,24,25,26].

In this study, we employed high-throughput sequencing (HTS) to globally profile circulating miRNA expression. This was followed by confirmative reverse transcription-quantitative PCR (RT-qPCR) to determine differential miRNA expression in CFS/ME.

Materials and Methods

Participants

CFS/ME patients (n = 20, age = 44.5 ± 6.0 years) were recruited from a South-East Queensland patient database in Australia. Inclusion criteria for the CFS/ME participants were according to the American CDC 1994 case definition [26]. Non-fatigued controls (n = 20, age = 47.3 ± 6.7 years) were recruited mainly from the general public, and were participants with no medical history or symptoms of persistent fatigue or illness. Individuals who were smokers, pregnant/breast-feeding or immobile were excluded from the study, as were individuals with autoimmune, thyroid or cardiac related disorders prior to the onset of CFS/ME. This
project was approved by the Bond University Human Research Ethics Committee (BUHREC), approval number R0852A. All participants in the study provided informed and written consent prior to involvement in the study.

Sample processing and RNA extraction
Plasma harvesting was performed immediately after peripheral blood collection. Briefly 10 mL of whole blood was collected from each participant into EDTA collection tubes. Plasma was immediately separated via centrifugation at 5000 × g for 10 min, and 5 mL of the plasma was transferred to a new tube and stored at -80°C. Prior to RNA extraction, the plasma samples were centrifuged for 10 min at 16,000 × g at 4°C in order to remove any cellular debris left in the plasma. Circulating RNA was extracted from plasma using the miRNeasy Serum/Plasma kit (Qiagen, Hilden, Germany) according to manufacturer's instruction with minor modifications. Briefly, 1 mL of plasma was incubated with 5 mL of Qiazol Lysis Reagent for 10 min. Samples were processed using a vacuum manifold to help process the larger quantity of plasma. An additional 80% ethanol wash step was included and sample elution was performed twice using 15 μL of RNase-free water. The size, quantity and quality of the extracted circulating RNA was assessed using a small RNA chip on an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA).

MicroRNA profiling by HiSeq2000 sequencing
The six CFS/ME patients and six non-fatigued controls with the highest abundance of small RNA were used for HTS. Small RNA libraries were constructed using the TruSeq Small RNA Sample Preparation kit (Illumina, San Diego, CA) according to the manufacturer’s protocols. Briefly, small RNA samples (5–10 ng) were ligated with 5’ and 3’ adapters, followed by reverse transcription-PCR (RT-PCR) for cDNA library construction and incorporation of index tags. The cDNA library fragments were purified separated on a 6% TBE PAGE gel and 145–160 bp size fraction containing miRNA inserts was isolated. The twelve cDNA library samples were pooled in equimolar amounts and used for cluster generation and sequence analysis in a single lane on an Illumina HiSeq2000 (50 bp single read). This work was performed at the Australian Genome Research Facility (AGRF).

Sequencing data analysis
Raw FASTQ sequences were generated and demultiplexed using the Illumina CASAVA v1.8 pipeline. Per base sequence quality (quality score >30) was then assessed using the FastQC toolkit [27]. Prior to mapping the read data was pre-processed using the UEA small RNA Workbench (http://sma-workbench.cmp.uwa.ac.uk) [27]. Briefly, the 3’ adapter sequences were trimmed, the read size filtered (16–35 nt), unique reads counted and low abundance reads (<10 reads) discarded. Unique sequence reads were then aligned to the human genome (hg18) and miRBase_v16 using the miRanalyzer web server tool (http://bioinfo2.ugr.es/mirana/mirana.php) [28]. Raw reads of the sequencing data are available at the NCBI Sequence Read Archive (SRA). Data are accessible through NCBI Bioproject accession number PRJNA219428 at http://www.ncbi.nlm.nih.gov/bioproject/.

Quantification of miRNA by RT-qPCR
The expression of eight miRNAs was validated using PerFeCTa miRNA primers (Quanta Biosciences, Gaithersburg, MD). In addition four miRNAs (miR-10, miR-15b, miR-16 and miR-24) were assessed for their suitability as a stable reference gene. Briefly, 15 μL of extracted RNA were reverse transcribed into cDNA using the NCode miRNA First-Strand cDNA Synthesis kit (Life Technologies, Carlsbad, CA). RT-qPCR was performed as previously described [4].

Statistical analyses
Mann-Whitney rank sum test was used in analysing differences between the CFS/ME patients and non-fatigued controls regarding age and haematological characteristics (Table 1 and 2). For RT-qPCR analysis unpaired groups of values were compared according to the non-parametric Mann-Whitney U test. These data were analysed using GraphPad Prism 5 (GraphPad Software, San Diego, CA). Differential expression of the miRNA-Seq raw count data was assessed using the BioC/R package DESeq [29]. Due to the small sample size and the heterogeneity of the CFS/ME phenotype we interpreted significance from the unadjusted P-value, without the Benjamini-Hochberg method for False Discovery (FDR) correction. Statistical significance was accepted at P<0.05.

Results
Subject characteristics
The age of the study participants was recorded and a full blood count performed on whole blood samples prior to plasma separation. There were no significant differences between age or full blood count values in the CFS/ME and control groups (Table 1). For sequencing, a subset of six CFS/ME and six non-fatigued control samples were selected. A significant difference in lymphocyte and granulocyte percentages, lymphocyte count and red blood cell distribution width between the CFS/ME and control groups was observed in these subsets (Table 2).

Illumina high-throughput sequencing of plasma miRNA in CFS/ME
To select for candidate plasma miRNAs differentially expressed in CFS/ME, we performed an initial genome-wide small RNA screening of six CFS/ME patients and six non-fatigued controls by Illumina HTS. A total of 154,989,205 reads were generated from a single flow cell lane on the HiSeq2000 sequencer. After demultiplexing an average of 12 million reads per library was obtained. Initial analysis of the library read lengths demonstrated a bimodal distribution of reads with peaks at 22 and 32 nucleotides (Figure S1). These populations were subsequently found to contain miRNA and long non-coding RNA (lncRNA) sequences respectively. On average 57.4% of decoded sequences were mappable, with 97.5% of mappable reads aligning to the human genome (hg18). Mature miRNA constituted 17% of all mapped reads, whilst other RNA species (including lncRNA and snoRNA) constituted 80.5% of mapped reads (Figure 1A). 75.1% of the mapped other RNA species consisted of lncRNA known as R-assiated RNA Y4 (RNY4) which is the main component of the 32–33 nucleotide population. When examining unique reads, miRNA comprised 44.3% of all unique reads mapped whilst other RNA species comprised only 7% (Figure 1B).

miRNA characterisation
A total of 373 mature miRNA were initially identified in one or more samples based on sequence alignment to the miRBase registry (release 19). The top 23 expressed miRNAs in each sample group are listed in Table 3. Furthermore, 13 novel candidate miRNAs were predicted, although these amounted to a very small fraction of the total read count. However, none of these novel
miRNA showed significant differences between CFS/ME and non-fatigued controls (Table S1).

**Differential expression of plasma miRNA in CFS**

Differential expression of identified miRNAs from miRBase was calculated using DESeq. A total of 19 microRNAs were significantly dysregulated in CFS/ME compared to non-fatigued controls (Table 4). Of the 19 differentially expressed miRNAs 16 were considered low in abundance due to a base mean count of less than 1,000 reads, their detection was found to be unreliable for confirmative RT-qPCR. The remaining three miRNAs (hsa-

### Table 1. Characteristics of CFS/ME and non-fatigued control participants.

| Parameters                        | Non-Fatigued (n = 20)       | CFS/ME (n = 20)       | *P*-values |
|-----------------------------------|-----------------------------|-----------------------|------------|
| Age                               | 47.3 ± 6.7                  | 44.5 ± 6.0            | 0.24       |
| White Blood Cells (10^3/μL)       | 6.19 ± 1.58                 | 5.53 ± 1.45           | 0.12       |
| Lymphocytes (%)                   | 35.89 ± 8.81                | 34.80 ± 6.41          | 0.53       |
| Monocytes (%)                     | 6.72 ± 1.60                 | 6.96 ± 1.77           | 0.66       |
| Granulocytes (%)                  | 57.39 ± 8.94                | 58.25 ± 6.49          | 0.74       |
| Lymphocytes (x10^3/μL)            | 2.14 ± 0.53                 | 1.89 ± 0.46           | 0.13       |
| Monocytes (x10^3/μL)              | 0.41 ± 0.12                 | 0.39 ± 0.15           | 0.66       |
| Granulocytes (x10^3/μL)           | 3.64 ± 1.53                 | 3.25 ± 1.05           | 0.36       |
| Red Blood Cells (x10^6/μL)        | 4.20 ± 0.36                 | 4.13 ± 0.24           | 0.43       |
| Haemoglobin (g/L)                 | 133.68 ± 8.52               | 132.20 ± 7.88         | 0.40       |
| Haematocrit (%)                   | 37.14 ± 1.95                | 36.67 ± 2.10          | 0.40       |
| Mean Cell Volume (fl)             | 88.82 ± 5.39                | 88.69 ± 2.58          | 0.51       |
| Mean Cell Haemoglobin (pg)        | 31.97 ± 2.01                | 32.02 ± 2.13          | 0.78       |
| Red Blood Cell Distribution Width (%) | 12.52 ± 1.28                | 12.44 ± 0.69          | 0.41       |
| Platelet (x10^3/μL)               | 231.06 ± 88.61              | 243.80 ± 53.20        | 0.38       |
| Mean Platelet Volume (fl)         | 7.59 ± 0.77                 | 7.63 ± 1.16           | 0.72       |

* Denotes statistical significance set at P < 0.05. The blood characteristics of the participants in the study are presented below following full blood count analysis.

doi:10.1371/journal.pone.0102783.t001

### Table 2. Characteristics of miRNA-Seq subset of CFS/ME and non-fatigued control participants.

| Parameters                        | Non-Fatigued (n = 6)       | CFS/ME (n = 6)       | *P*-values |
|-----------------------------------|-----------------------------|----------------------|------------|
| Age                               | 48.8 ± 8.0                  | 41.7 ± 4.8           | 0.09       |
| White Blood Cells (10^3/μL)       | 6.23 ± 0.83                 | 5.67 ± 1.60          | 0.70       |
| Lymphocytes (%)                   | 41.30 ± 5.50                | 33.27 ± 6.46         | 0.09       |
| Monocytes (%)                     | 7.02 ± 1.20                 | 6.42 ± 1.22          | 0.49       |
| Granulocytes (%)                  | 51.68 ± 5.28                | 60.32 ± 6.02         | 0.04*      |
| Lymphocytes (x10^3/μL)            | 2.58 ± 0.53                 | 1.83 ± 0.48          | 0.03*      |
| Monocytes (x10^3/μL)              | 0.43 ± 0.08                 | 0.37 ± 0.16          | 0.49       |
| Granulocytes (x10^3/μL)           | 3.22 ± 0.49                 | 3.45 ± 1.09          | 0.39       |
| Red Blood Cells (x10^6/μL)        | 4.24 ± 0.39                 | 4.06 ± 0.26          | 0.24       |
| Haemoglobin (g/L)                 | 134.67 ± 9.69               | 132.33 ± 8.76        | 0.49       |
| Haematocrit (%)                   | 37.35 ± 2.09                | 36.47 ± 2.32         | 0.49       |
| Mean Cell Volume (fl)             | 88.25 ± 3.95                | 88.87 ± 2.15         | 0.94       |
| Mean Cell Haemoglobin (pg)        | 31.78 ± 0.95                | 32.30 ± 0.80         | 0.24       |
| Mean Corpuscular Haemoglobin Concentration (g/L) | 360.33 ± 8.41               | 363.33 ± 0.37        | 0.49       |
| Red Blood Cell Distribution Width (%) | 12.03 ± 0.47                | 12.62 ± 0.37         | 0.03*      |
| Platelet (x10^3/μL)               | 248.17 ± 85.41              | 237.17 ± 41.39       | 0.70       |
| Mean Platelet Volume (fl)         | 7.58 ± 0.80                 | 6.90 ± 0.86          | 0.24       |

* Denotes statistical significance set at P < 0.05. The blood characteristics of the participants chosen for sequencing analysis.

doi:10.1371/journal.pone.0102783.t002
miR127-3p, hsa-miR-142-5p and hsa-miR-143-3p) were all upregulated in CFS/ME compared to non-fatigued controls.

RT-qPCR confirmation of plasma miRNA-Seq data

The choice of a stable reference gene is critical for accurate gene expression analysis by RT-qPCR. Of the four putative reference genes tested hsa-miR-16-5p was determined to be the most stably expressed (Figure 2). To validate the RNA-Seq results (n = 6/group) we performed RT-qPCR in an expanded sample cohort (n = 20/group). Three differentially expressed miRNAs (hsa-miR127-3p, hsa-miR-142-5p and hsa-miR-143-3p) and four non-differentially expressed miRNAs (hsa-miR-21-5p, hsa-miR-

Table 3. Top 25 most abundant miRNAs identified.

| miRNA ID  | Rank (Non-Fatigued) | Base Mean (Non-Fatigued) | Rank (CFS/ME) | Base Mean (CFS/ME) |
|-----------|---------------------|--------------------------|---------------|-------------------|
| hsa-miR-486-5p | 1                  | 232,025                  | 1             | 206,637           |
| hsa-miR-191-5p | 2                  | 163,282                  | 2             | 161,507           |
| hsa-miR-92a-3p | 3                  | 122,247                  | 3             | 112,091           |
| hsa-miR-22-3p  | 4                  | 98,273                   | 4             | 102,010           |
| hsa-miR-30d-5p | 5                  | 64,038                   | 5             | 58,586            |
| hsa-miR-26a-5p | 6                  | 56,084                   | 6             | 54,753            |
| hsa-miR-181a-5p| 7                  | 49,098                   | 7             | 37,346            |
| hsa-miR-151a-3p| 8                  | 35,388                   | 8             | 33,991            |
| hsa-miR-423-5p | 9                  | 34,660                   | 9             | 33,841            |
| hsa-miR-16-5p  | 10                 | 32,226                   | 10            | 27,914            |
| hsa-miR-150-5p | 11                 | 20,792                   | 12            | 16,977            |
| hsa-miR-126-5p | 12                 | 17,096                   | 11            | 17,960            |
| hsa-miR-25-3p  | 13                 | 12,834                   | 16            | 10,555            |
| hsa-miR-28-3p  | 14                 | 12,733                   | 14            | 13,057            |
| hsa-miR-30e-5p | 15                 | 12,559                   | 13            | 13,146            |
| hsa-miR-186-5p | 16                 | 11,374                   | 17            | 10,153            |
| hsa-miR-151a-5p| 17                 | 9,241                    | 18            | 8,655             |
| hsa-miR-127-3p | 18                 | 8,750                    | 15            | 12,961            |
| hsa-miR-10a-5p | 19                 | 8,093                    | 22            | 6,443             |
| hsa-miR-423-3p | 20                 | 7,619                    | 19            | 7,856             |
| hsa-miR-451a   | 21                 | 6,451                    | 23            | 6,292             |
| hsa-miR-140-3p | 22                 | 6,252                    | 25            | 5,895             |
| hsa-miR-27b-3p | 23                 | 6,093                    | 20            | 7,497             |
| hsa-miR-146a-5p| 24                 | 5,994                    | 21            | 7,246             |
| hsa-miR-221-3p | 25                 | 5,749                    | 29            | 4,863             |

1 The base mean is the mean of the counts for each miRNA divided by the size factor for each condition (as calculated by DESeq).

doi:10.1371/journal.pone.0102783.t003
103-3p, hsa-miR-146a-5p and hsa-miR-223-3p) were selected and their expression levels quantified using RT-qPCR. The four non-differentially expressed miRNAs were selected as they previously demonstrated dysregulation in cytotoxic lymphocytes in CFS/ME patients [3], although HTS did not identify differential expression in plasma. All RT-qPCR results for the remaining three miRNAs were consistent with the RNA-Seq data (Figure 3).

**Discussion**

To date, screening for CFS/ME has been based on well-established case definitions [3,30]. Profiling of circulating miRNA levels may serve to enhance the molecular diagnosis of CFS/ME. Using Illumina HTS, the present study identified 19 miRNAs that were differentially expressed in CFS/ME patients. Of these, only three were confirmed to be highly abundant in the CFS/ME patients in comparison to the controls. These results suggest that miR-127-3p, miR-143-3p and miR-142-5p may be implicated in the pathogenesis of CFS/ME.

Although, there is currently no definitive source identified for the presence of miRNAs in biofluids, blood cells in particular reticulocytes, myeloid cells, lymphoid cells, platelets, cells from the liver, lungs and kidneys or lysed cells may release miRNAs into the circulation [31,32,33]. Similarly, miRNAs may be discharged into the plasma following tissue damage for example, circulating miR-1 and miR-133a, are significantly increased following acute myocardial infarction [34]. The miRNAs in the present study have expressions in various tissues. MiR-127-3p is found in the testicular and nervous system [35], miR-143-3p is expressed in the colon [36] while miR-142-5p is expressed by cells of the immune system [37,38]. However, both miR-142-5p and miR-143-3p are reported to be amongst the miRNAs frequently found in plasma and serum [32]. Over-expression of miR-142-5p has been observed in most cancer-related and immunological disorders [39]. This particular miRNA is abundant in most hematopoietic cell lines and may be involved in thwarting inflammatory processes.

**Table 4.** miRNAs differentially expressed between CFS/ME and non-fatigued controls.

| miRNA ID   | Base Mean1 (Non-Fatigued) | Base Mean1 (CFS/ME) | Fold Change | P-value |
|------------|---------------------------|---------------------|-------------|---------|
| **High-Abundance miRNAs** | | | | |
| hsa-miR-127-3p | 8,751.91 | 12,978.10 | 1.48 | 0.0476 |
| hsa-miR-143-3p | 2,060.61 | 4,439.17 | 2.15 | 0.0005 |
| hsa-miR-142-5p | 994.22 | 1,811.23 | 1.82 | 0.0443 |
| **Low-Abundance miRNAs** | | | | |
| hsa-miR-331-3p | 366.94 | 590.85 | 1.61 | 0.0277 |
| hsa-miR-381-3p | 347.35 | 550.72 | 1.59 | 0.0336 |
| hsa-miR-136-3p | 125.63 | 224.69 | 1.79 | 0.0213 |
| hsa-miR-370 | 59.84 | 130.44 | 2.18 | 0.0051 |
| hsa-miR-493-5p | 39.87 | 82.49 | 2.07 | 0.0263 |
| hsa-miR-4532 | 10.47 | 78.06 | 7.45 | 0.0002 |
| hsa-miR-450b-5p | 1.72 | 1.23 | 0.71 | 0.0208 |
| hsa-miR-26a-1-3p | 1.56 | 1.16 | 0.75 | 0.0106 |
| hsa-mir-126* | 1.39 | 0.91 | 0.65 | 0.0449 |
| hsa-miR-5187-3p | 1.31 | 1.10 | 0.84 | 0.0217 |
| hsa-miR-641 | 1.07 | 0.78 | 0.73 | 0.0240 |
| hsa-miR-548j | 1.07 | 1.10 | 1.03 | 0.0446 |
| hsa-miR-3065-3p | 0.90 | 0.71 | 0.79 | 0.0126 |
| hsa-miR-16-2-3p | 0.82 | 0.71 | 0.87 | 0.0128 |
| hsa-let-7g-3p | 0.82 | 0.78 | 0.95 | 0.0251 |
| hsa-miR-548ax | 0.82 | 0.91 | 1.11 | 0.0484 |

1The base mean is the mean of the counts for each miRNA divided by the size factor for each condition (as calculated by DESeq).

*The complementary analog for miR-126.

![Figure 2. Expression stability values (M) of the putative reference genes tested in plasma.](image-url)

The expression of four genes was analysed to determine the most suitable reference gene. MicroRNAs are ranked from the most stable to the least stable (left to right). The dotted line indicates the recommended threshold value of <1.0 for heterogeneous samples.

![Figure 3. Expression stability values (M) of the putative reference genes tested in plasma.](image-url)
over expression of CFS/ME equivocal levels of IL-10 have been reported and an upregulation may result in significant increases in IL-10 [54]. In therefore by dampening BCL6 as a consequence of p53 expression [53]. BCL6 inhibits the production of IL-10 and upregulations have been shown to increase apoptosis [52].

miR-143-3p or cancer cell proliferation and promoting apoptosis [46]. As it may act to reduce BCL2 mRNA thereby preventing tumour cell stagnates the growth of tumours and cancer cells [45]. Overexpression of oncogene KRAS [44]. In Systemic Lupus Erythematosus (SLE), increased expression of miR-142-5p in CD4+ T cells prevents autoimmunity while a downregulation may result in autoreactive T cells and hyperactive B cells [41].

miR-142-5p is important for T cell development where it targets SLAM associate protein (SAP). Inhibition of miR-142-5p may increase the expression of CD84, IL-10, SAP and IgG production [41]. CD84 is an important T cell regulatory marker as it regulates cytokine production, function, adhesion and interaction with B cells [42]. The levels of IL-10 have been shown to be equivocal in CFS/ME patients. The cause of an increase in miR-142-5p is unknown, however, it is likely that this may be related to heightened Treg suppression and additional autoimmune responses.

miR-143-3p targets IgG FCγ receptor 1 and also CD64 reducing lung inflammation. It is a tumour suppressor gene and is highly down regulated in colorectal cancer [43]. It inhibits the oncogene KRAS [44]. Overexpression of miR-143-3p in most cancer cells stagnates the growth of tumours and cancer cells [45] as it may act to reduce BCL2 mRNA thereby preventing tumour or cancer cell proliferation and promoting apoptosis [46]. miR-143-3p has been identified as a neutrophil specific miRNA [47]. Importantly, its expression is upregulated in cases of heightened erythropoiesis such as in polycythemia [48]. In CFS/ME increased levels of neutrophil apoptosis occurs in some patients [49,50,51], and this potentially ensues from high levels of miR-143-3p.

miR-127-3p interferes with ERK signalling, a tumour suppressor and upregulations have been shown to increase apoptosis [52]. Importantly, it targets BCL6 a transcription factor which increases p53 expression [53]. BCL6 inhibits the production of IL-10 therefore by dampening BCL6 as a consequence of miR-127 upregulation may result in significant increases in IL-10 [54]. In CFS/ME equivocal levels of IL-10 have been reported and an over expression of miR-127-3p may explain to some extent some of these patterns. BCL6 is an important transcription factor required for germinal centre B cell and follicular helper T cell development [55,56,57]. Irregularities in the expression of BCL6 may result in aberrant inflammatory responses and the development of various lymphomas [58].

The presence of a high proportion of the RNA Y4 within the small RNA sequencing libraries reduced miRNA sequencing capacity. Y RNAs are components of Ro ribonucleoproteins (RNP) and were first identified in the serum of patients with the autoimmune disorder lupus erythematosus [59]. Y RNAs are similar in size and structure to miRNAs as they both have comparable stem and loop structures [60]. These similarities may explain the presence of Y RNA following small RNA library construction. Efficient depletion of Y RNA would yield higher quality HTS miRNA data allowing deeper sequencing. Methods for the reduction of Y RNA in a similar manner to rRNA depletion could be employed to improve the ratio of useful miRNA data [61]. Most extracellular miRNA studies do not report on the abundance of Y RNAs in circulation and this may be related to the read size filtering used. Given that Y RNAs upon degradation produce two classes of fragments and majority of which bind to Ro60, it is possible to posit that these fragments that we observed in the plasma samples are those Y RNAs bound to Ro60.

Plasma miRNAs show great promise as potential non-invasive biomarkers, but at present the precise and accurate measurement is challenging. A number of factors including cellular contamination, haemolysis and low quantity can result in significant bias that does not reflect the original biological state of the sample. Current circulating miRNA research indicates that haemolysis may influence the availability of miRNAs in circulation [33]. Haemolysis may be evaluated in archival data by examining the delta Cq of miR-451 and miR-23a [33]. In healthy individuals, 194 miRNAs may be detected in both haemolysed and non-haemolysed blood samples, where 40.2% may be upregulated following haemolysis, 13% may be down regulated and 28.9% are unaffected by haemolysis [62,63]. In the present study, our three candidate miRNAs, miR-127-3p, miR-143-3p and miR-142-5p are among the miRNA genes unaffected by haemolysis in healthy individuals [62].

The benefit of circulating miRNAs as biomarkers for diseases relates to a number of characteristics such as reduced complexity compared to proteins, stability, conserved sequences in various species and restricted expression in specific tissues and biological processes. It has been suggested that 206 miRNAs are expressed in blood cells, serum and plasma, thus in most plasma and serum studies it is highly necessary to observe strict sample processing procedures to ensure the samples are cell free [64]. Cellular content contamination of biofluids may be reduced by employing additional centrifugation steps during the initial plasma separation to lessen potential contamination from cellular debris and haemolysis [65]. Additionally, it may be important to assess blood cell counts and lysis during sample collection as variation in plasma levels of miRNAs in some cases have been credited to circulating blood cell effects [66,67]. Starting concentration of miRNA levels vary among individuals due to age, sex and other factors and this may significantly impact the outcomes of various expression studies [68,69]. To date there are no established reference values for miRNAs among normal individuals and this may be necessary for diagnostic marker purposes, hence, the inclusion of appropriate calibrator controls during RT-qPCR analysis is necessary. Nonetheless, despite these challenges, miRNA signatures from normal individuals are reproducible with similar expression patterns and a limited amount of variability [32,70].
Conclusions

The present study suggests that plasma may be a satisfactory parameter for determining miRNAs as biomarkers in CFS/ME. The data illustrates that miR-127-3p, miR-142-5p and miR-143-3p may be potential plasma biomarkers for CFS/ME diagnosis. However, further studies are now required to validate these findings in a larger cohort to ascertain diagnostic power of these findings. The shortcomings with using biofluid is the low abundance of RNA thus a large quantity of sample is often required to achieve high yields and quality of RNA. Presently, the use of HTS as a means to detecting possible changes in miRNAs in disease presentations is in its infancy. Further studies are required to evaluate and refine the method to promote better detection and reliable data that can be replicated across studies.

Supporting Information

Figure S1 Length distribution of sequenced small RNA. Data represents mean ± SEM (n = 6/group). (TIF)

Table S1 Novel miRNA candidates as predicted by miRanalyzer. (DOCX)

Acknowledgments

The authors would like to acknowledge Mr. Gunn Atkinson for his contribution to this project.

Author Contributions

Conceived and designed the experiments: EWB KJA JB DRS SMG. Performed the experiments: EWB JB KJA. Analyzed the data: EWB JB KJA SMG. Contributed reagents/materials/analysis tools: SMG DRS. Wrote the paper: EWB JB KJA SMG DRS.

References

1. Prins JB, van der Meer JW, Bleijenberg G (2006) Chronic fatigue syndrome. Lancet 367: 346–355.
2. Johnston S, Brenu EW, Staines DR, Marshall-Gradini S (2013) The prevalence of chronic fatigue syndrome/myalgic encephalomyelitis: a meta-analysis. Clin Epidemiol 5: 103–110.
3. Fakada K, Strauss SE, Hickie I, Sharpe MC, Dobbins JG, et al. (1994) The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 121: 953–959.
4. Brenu EW, Ashton KJ, van Driel ML, Staines DR, Peterson D, et al. (2012) Cytotoxic lymphocyte microRNAs as prospective biomarkers for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. J Affect Disord 141: 261–269.
5. Brenu EW, van Driel ML, Staines DR, Ashton KJ, Hardcastle SL, et al. (2012) Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med 10: 88.
6. Brenu EW, Staines DR, Baskurt OK, Ashton KJ, Ramos SB, et al. (2010) Immune and hemorheological changes in chronic fatigue syndrome. J Transl Med 8: 1.
7. Kaushik N, Fear D, Richards SC, McDermott CR, Nuwaysir EF, et al. (2005) Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome. J Clin Pathol 58: 826–832.
8. Farrant D, Kerr J, Harrison TJJ, Kellam P (2011) Assessment of a 44 gene classifier for the evaluation of chronic fatigue syndrome from peripheral mononuclear blood cell gene expression. PLoS One 6: e16872.
9. Kerr JR (2008) Gene profiling of patients with chronic fatigue syndrome/myalgic encephalomyelitis. Curr Rheumatol Rep 10: 492–494.
10. Kerr JR, Petty R, Burke B, Gough J, Fear D, et al. (2006) Gene expression subtypes in patients with chronic fatigue syndrome/myalgic encephalomyelitis. J Infect Dis 197: 1171–1184.
11. Kerr JR, Burke B, Petty R, Gough J, Fear D, et al. (2008) Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis: a detailed analysis of gene networks and clinical phenotypes. J Clin Pathol 61: 730–739.
12. Brenu EW, van Driel MI, Staines DR, Ashton KJ, Ramos SB, et al. (2011) Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. J Transl Med 9: 81.
13. Sun W, Julie LiYS, Huang HD, Shyy JY, Chien S (2010) microRNA: a master regulator of cellular processes for bioengineering systems. Annu Rev Biomed Eng 12: 1–27.
14. Xiao C, Rajewsky K (2009) MicroRNA control in the immune system: basic principles. Cell 136: 26–36.
15. Chen CZ, Schaffert S, Frangos R, Loh C (2013) Regulation of immune responses and tolerance: the microRNA perspective. Immunol Rev 253: 112–126.
16. Long JM, Lahiri DK (2012) Advances in microRNA experimental approaches to study physiological regulation of gene products implicated in CNS disorders. Exp Neurol 235: 492–410.
17. Nakamoto M, Jin P, O'Donnell WT, Warren ST (2005) Physiological identification of human transcripts transcriptionally regulated by a specific miRNA. Hum Mol Genet 14: 3013–3021.
18. Jansson MD, Lund AH (2012) MicroRNA and cancer. Mol Oncol 6: 590–610.
19. Mo YY (2012) MicroRNA regulatory networks and human disease. Cell Mol Life Sci 69: 3529–3531.
20. Shafi G, Aliva N, Munshi A (2013) MicroRNA signatures in neurological disorders. Can J Neurol Sci 37: 177–185.

Circulating MiRNAs in CFS/ME

21. Qiú C, Chen G, Guí Q (2012) Towards the understanding of microRNA and environmental factor interactions and their relationships to human diseases. Sci Rep 2: 318.
22. Kroh EM, Parkin RK, Mitchell PS, Tewari M (2010) Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50: 298–301.
23. Hu J, Wang Z, Tan CJ, Liao BY, Zhang X, et al. (2013) Plasma microRNA, a potential biomarker for acute rejection after liver transplantation. Transplantation 95: 991–999.
24. Illan-Mutlu A, Wagner L, Wohrer A, Furtner J, Widhalm G, et al. (2012) Plasma MicroRNA-21 concentration may be a useful biomarker in globlastoma patients. Cancer Invest 30: 615–621.
25. Zhang Y, Ju Y, Zheng R, Guo Y, Wang Y, et al. (2010) Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 56: 1830–1838.
26. Adachi T, Nakamishi M, Osuka Y, Nishimura K, Hirokawa G, et al. (2010) Plasma microRNA-499 as a biomarker of acute myocardial infarction. Clin Chem 56: 1183–1185.
27. Stocks MB, Moxon S, Mapleson D, Woolfenden HC, Mohoriana I, et al. (2012) The UEA sRNA workbench: a suite of tools for analysing and visualizing next generation sequencing microRNA and small RNA datasets. Bioinformatics 28: 2629–2631.
28. Hackenberg M, Sturm M, Langenberger D, Falcon-Perez JM, Arasamz AM (2009) miRanalyzer: a microRNA detection and analysis tool for next-generation sequencing experiments. Nucleic Acids Res 37: W618–W616.
29. Anders S, Huber W (2010) Differential expression analysis for sequence count data. Genome Biol 11: R106.
30. Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, et al. (2011) Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med 270: 327–338.
31. Peinchaud CC, Cheng HHL, Tewari M (2012) MicroRNA profiling: approaches and considerations. Nat Rev Genet 13: 358–369.
32. Duttagupta R, Jiang R, Goelhi J, Getts RC, Jones KW (2011) Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One 6: e20769.
33. Turchinovich A, Weiz L, Langheinz A, Burwinkel B (2011) Characterization of extracellular circulating microRNA. Nucleic Acids Res 39: 7223–7233.
34. D’Alessandra Y, Devanna P, Limana F, Straino S, Di Carlo A, et al. (2010) Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 31: 2765–2773.
35. Robertus JL, Harms G, Blokzijl T, Booman M, de Jong D, et al. (2009) Specific miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. Mod Pathol 22: 547–555.
36. Zhang Y, Wang Z, Chen M, Peng L, Wang X, et al. (2012) Plasma MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer 11: 23.
37. Ansel KM (2013) RNA regulation of the immune system. Immuno Rev 253: 5–11.
38. Mo VR, Dumar CI, Scan MJ, Gehrau RC, Maluf DG (2013) MicroRNAs as biomarkers in solid organ transplantation. Am J Transplant 13: 11–19.
39. Saito Y, Suzuki H, Tsugawa H, Imaeda H, Matsuzaki J, et al. (2012) Overexpression of miR-142-5p and miR-155 in gastric mucosa-associated lymphoid tissue (MALT) lymphoma resistant to Helicobacter pylori eradication. PLoS One 7: e47396.
40. Merkereva M, Belickova M, Bruchova H (2008) Differential expression of microRNAs in hematopoietic cell lineages. Eur J Haematol 81: 304–310.
41. Ding S, Liang Y, Zhao M, Liang G, Long H, et al. (2012) Decreased microRNA-142-3p/5p expression causes CD4+ T cell activation and B cell hyperstimulation in systemic lupus erythematosus. Arthritis Rheum 64: 2953–2963.

42. Cannons JL, Qi H, Lu KT, Dutta M, Gomez-Rodriguez J, et al. (2010) Optimal germinal center responses require a multistage T cell:B cell adhesion process involving integrins, SLAM-associated protein, and CD40. Immunity 32: 253–265.

43. Shaly O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, et al. (2007) Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 72: 397–402.

44. Chen X, Guo X, Zhang H, Xiang Y, Chen J, et al. (2008) Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 28: 1383–1392.

45. Peschiardi A, Giacobbe A, Formosa A, Markert EK, Bongiorno-Borbone L, et al. (2013) miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene 32: 797–802.

46. Liu L, Yu X, Guo X, Tian Z, Su M, et al. (2012) miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. Mol Med Rep 5: 753–760.

47. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, et al. (2007) Effects of chromatin-modifying drugs on microRNA-127 expression with downregulation of the proto-oncogene BCL6 by chromatin-remodeling proteins Jmjd2a and Jmjd2c. Mol Cancer 7: e29979.

48. Allantaz F, Cheng DT, Bergauer T, Ravindran P, Rossier MF, et al. (2012) Optimal microRNA extraction of peripheral blood mononuclear cells. J Transl Med 7: 39.

49. Kennedy G, Spence V, Underwood C, Belch JJ (2004) Increased neutrophil apoptosis in chronic fatigue syndrome. J Clin Pathol 57: 891–893.

50. Chen X, Ba Y, Ma L, Cai X, Yin Y, et al. (2008) MicroRNA-127 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. Mol Med Rep 5: 753–760.

51. Vojdani A, Mordechai E, Brautbar N (1997) Abnormal apoptosis and cell cycle progression in humans exposed to methyl tertiary-butyl ether and benzene contaminating water. Hum Exp Toxicol 16: 485–494.

52. Mosakhani N, Sarhadi VK, Boroe I, Karjalainen-Lindberg ML, Sundstrom J, et al. (2012) MicroRNA profiling differentiates colorectal cancer according to KRAS status. Genes Chromosomes Cancer 51: 1–9.

53. Parpart S, Wang XW (2013) MicroRNA regulation and its consequences in cancer. Curr Pathobiol Rep 1: 71–79.

54. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, et al. (2006) Specific activation of microRNA-127 with downregulation of the proto-oncogene Bcl6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9: 435–443.

55. Crotty S, Johnston RJ, Schoenberger SP (2010) Effector and memory B cells of the germinal center: role in B-cell physiology and malignancy. Nat Rev Immunol 8: 22–33.

56. Pritchard CC, Kroh EM, Chien JW, et al. (2013) Plasma Processing Conditions Substantially Influence Circulating microRNA Biomarker Levels. PLoS One 8: e64795.

57. McAlexander MA, Phillips MJ, Witwer KW (2013) Comparison of Methods for miRNA Extraction from Plasma and Quantitative Recovery of RNA from Cerebrospinal Fluid. Front Genet 4: 83.

58. Kirschner MB, van Zandwijk N, Reid G (2013) Cell-free microRNAs: potential biomarkers in need of standardized reporting. Front Genet 4: 56.

59. Verhagen AP, Pijnappel GJ (2011) Are the Ro RNP-associated Y RNAs concealing other diseases? Cell Res 18: 997–1006.

60. Verhagen AP, Pijnappel GJ (2011) Are the Ro RNP-associated Y RNAs concealing other diseases? Cell Res 18: 997–1006.

61. O’Neil D, Ghantous R, Schlumberger M (2013) Ribosomal RNA Depletion for Efficient Use of RNA-Seq Capacity. Curr Protoc Mol Biol Chapter 4: Unit 19.

62. Kirschner MB, Edelman JJ, Varmus HE, Varmus HE, et al. (2013) MicroRNA Extraction from Plasma and Quantitative Recovery of RNA from Cerebrospinal Fluid. Front Genet 4: 83.

63. Kirschner MB, van Zandwijk N, Reid G (2013) Cell-free microRNAs: potential biomarkers in need of standardized reporting. Front Genet 4: 56.

64. Cheng HH, Yi HS, Kim Y, Kroh EM, Chien JW, et al. (2013) Plasma Processing Conditions Substantially Influence Circulating microRNA Biomarker Levels. PLoS One 8: e64795.

65. Duttagupta R, Jones KW (2013) The curious case of miRNAs in circulation: miRNAs? Y RNA-derived miRNAs may be involved in autoimmunity. Bioessays 35: 674–682.

66. Pritchard CC, Kroh EM, Cai X, Yin Y, et al. (2008) Characterization of microRNA-127 expression in chronic fatigue syndrome. Integr Physiol Behav Sci 33: 296–300.

67. Verhagen AP, Pijnappel GJ (2011) Are the Ro RNP-associated Y RNAs concealing other diseases? Cell Res 18: 997–1006.